Natural Killer Cells in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - A Review of the Literature.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Original Publication: [Lausanne : Frontiers Research Foundation]

Autoimmunity*; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*etiology ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*metabolism ; Antibodies, Antineutrophil Cytoplasmic/*immunology ; Killer Cells, Natural/*immunology ; Killer Cells, Natural/*metabolism; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis ; Antibody-Dependent Cell Cytotoxicity/immunology ; Autoimmune Diseases/etiology ; Autoimmune Diseases/metabolism ; Autoimmune Diseases/pathology ; Biomarkers ; Cytokines/metabolism ; Diagnosis, Differential ; Disease Susceptibility ; Humans ; Organ Specificity/immunology

Anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) is a group of systemic autoimmune diseases characterized by inflammation of small- and medium-sized vessels. The three main types of AAV are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). A growing number of studies focus on natural killer (NK) cells in AAV. NK cells are innate lymphoid cells with important roles in anti-viral and anti-tumor defense, but their roles in the pathogenesis of autoimmunity is less well established. In this review, we will present a summary of what is known about the number, phenotype and function of NK cells in patients with AAV. We review the literature on NK cells in the circulation of AAV patients, studies on tissue resident NK cells and how the treatment affects NK cells.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Fuchs, Scheffschick, Gunnarsson and Brauner.)

Arthritis Res Ther. 2019 Dec 11;21(1):277. (PMID: 31829278)
J Leukoc Biol. 2019 Jun;105(6):1319-1329. (PMID: 31107565)
Int J Mol Sci. 2018 Mar 10;19(3):. (PMID: 29534427)
Immunity. 2016 May 17;44(5):1034-51. (PMID: 27192568)
Front Immunol. 2016 Oct 06;7:402. (PMID: 27766097)
Front Immunol. 2014 Feb 04;5:27. (PMID: 24550913)
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5115-20. (PMID: 17360338)
Arthritis Res Ther. 2015 Nov 21;17:337. (PMID: 26589807)
Arthritis Rheum. 2002 Jul;46(7):1763-72. (PMID: 12124859)
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):728-32. (PMID: 21187373)
Clin Immunol. 2008 May;127(2):144-50. (PMID: 18313361)
Sci Rep. 2020 Apr 3;10(1):5858. (PMID: 32246007)
Arthritis Rheum. 1999 Sep;42(9):1823-7. (PMID: 10513795)
J Autoimmun. 2016 Jun;70:73-9. (PMID: 27102145)
Am J Kidney Dis. 2020 Jan;75(1):124-137. (PMID: 31358311)
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):54-62. (PMID: 25516918)
Front Immunol. 2018 Aug 13;9:1869. (PMID: 30150991)
Lupus Sci Med. 2021 Sep;8(1):. (PMID: 34526357)
Arthritis Rheum. 2008 Jan;58(1):329-30. (PMID: 18163478)
Science. 2011 Jan 7;331(6013):44-9. (PMID: 21212348)
PLoS One. 2011;6(9):e24315. (PMID: 21915309)
Nat Commun. 2019 Nov 12;10(1):5120. (PMID: 31719529)
Nat Rev Rheumatol. 2014 Aug;10(8):484-93. (PMID: 24980139)
BMJ. 2020 Mar 18;368:m421. (PMID: 32188597)
J Leukoc Biol. 2015 Oct;98(4):479-87. (PMID: 26216938)
Blood. 2006 Jan 1;107(1):159-66. (PMID: 16150947)
PLoS One. 2016 May 11;11(5):e0154393. (PMID: 27166610)
J Clin Invest. 2017 Nov 1;127(11):4042-4058. (PMID: 28972539)
J Immunol. 2010 Mar 1;184(5):2272-80. (PMID: 20130214)
Clin Rheumatol. 2015 Jan;34(1):107-15. (PMID: 25388644)
Sci Rep. 2021 Jan 15;11(1):1551. (PMID: 33452360)
Front Immunol. 2021 Feb 25;12:622306. (PMID: 33717125)
N Engl J Med. 2012 Jul 19;367(3):214-23. (PMID: 22808956)
Nephrol Dial Transplant. 2021 Jul 23;36(8):1408-1417. (PMID: 32601673)
Arthritis Rheum. 2011 Jul;63(7):2116-26. (PMID: 21484763)
Biofactors. 2010 Jul-Aug;36(4):274-88. (PMID: 20623510)
Arthritis Res Ther. 2016 Sep 15;18(1):206. (PMID: 27629249)
Int J Mol Sci. 2020 Oct 03;21(19):. (PMID: 33023023)
Nat Rev Rheumatol. 2016 Oct;12(10):570-9. (PMID: 27464484)
Sci Rep. 2019 Feb 4;9(1):1351. (PMID: 30718650)
Cell Immunol. 1998 Dec 15;190(2):167-72. (PMID: 9878117)
Sci Immunol. 2020 Aug 7;5(50):. (PMID: 32769171)
Clin Exp Nephrol. 2013 Oct;17(5):628-630. (PMID: 23180035)
Front Med. 2018 Jun;12(3):269-279. (PMID: 29675689)
Arthritis Rheumatol. 2017 Jan;69(1):169-175. (PMID: 27482943)
J Leukoc Biol. 2019 May;105(5):955-971. (PMID: 30848847)
Eur J Immunol. 2004 Oct;34(10):2930-40. (PMID: 15368309)
Rheumatology (Oxford). 2017 Jul 1;56(7):1227-1237. (PMID: 28407142)
Lancet. 1999 Nov 6;354(9190):1598-603. (PMID: 10560675)
J Immunol. 2014 Apr 1;192(7):3399-408. (PMID: 24600034)
J Immunol. 2008 Jun 15;180(12):7785-91. (PMID: 18523242)
Trends Immunol. 2001 Nov;22(11):633-40. (PMID: 11698225)
N Engl J Med. 2010 Jul 15;363(3):211-20. (PMID: 20647198)
Acta Neurol Scand. 1993 Apr;87(4):318-21. (PMID: 8503263)
J Immunol. 2006 Dec 1;177(11):7833-40. (PMID: 17114454)
Cytometry B Clin Cytom. 2018 May;94(3):412-422. (PMID: 28834234)
Arthritis Rheumatol. 2021 Aug 25;:. (PMID: 34435471)
Cell Mol Immunol. 2019 May;16(5):430-441. (PMID: 30778167)
Cent Eur J Immunol. 2015;40(4):470-6. (PMID: 26862312)
BMC Immunol. 2021 Apr 12;22(1):26. (PMID: 33840389)
Blood. 2010 Nov 11;116(19):3865-74. (PMID: 20733159)
Eur J Haematol. 2004 Mar;72(3):203-12. (PMID: 14962239)
Hepatology. 2015 Dec;62(6):1817-27. (PMID: 26264889)
Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82. (PMID: 27162345)
J Immunol. 2004 Feb 1;172(3):1455-62. (PMID: 14734722)
Arthritis Rheum. 2006 Mar;54(3):992-7. (PMID: 16508981)
Clin Rheumatol. 2010 Mar;29(3):315-23. (PMID: 20012119)
Hematol Oncol Stem Cell Ther. 2015 Jun;8(2):47-55. (PMID: 25571788)
J Infect Dis. 2004 Apr 1;189(7):1193-8. (PMID: 15031787)
Nat Immunol. 2019 Jul;20(7):902-914. (PMID: 31209404)
Hum Pathol. 2001 Mar;32(3):320-6. (PMID: 11274642)
Autoimmun Rev. 2007 Apr;6(5):295-9. (PMID: 17412301)
Front Immunol. 2016 Dec 19;7:606. (PMID: 28066417)
Arthritis Res Ther. 2016 Sep 13;18(1):204. (PMID: 27624647)
Arthritis Rheum. 2013 Sep;65(9):2457-68. (PMID: 23740775)
Nat Immunol. 2008 May;9(5):503-10. (PMID: 18425107)
Scand J Rheumatol. 2012 Aug;41(4):298-304. (PMID: 22632143)
Front Cell Infect Microbiol. 2020 Feb 13;10:36. (PMID: 32117809)
Cytokine Growth Factor Rev. 2018 Aug;42:37-46. (PMID: 30122459)
J Lab Clin Med. 2006 May;147(5):242-9. (PMID: 16697772)
Clin Exp Immunol. 2018 Feb;191(2):180-188. (PMID: 28960271)
J Leukoc Biol. 2019 Jun;105(6):1275-1283. (PMID: 30811627)

Keywords: ANCA - associated vasculitis; anti-neutrophil cytoplasmic antibody; eosinophilic granulomatosis with polyangiitis (EGPA); granulomatosis with polyangiitis (GPA); microscopic polyangiitis (MPA); natural killer cells

0 (Antibodies, Antineutrophil Cytoplasmic)
0 (Biomarkers)
0 (Cytokines)

Date Created: 20220204 Date Completed: 20220224 Latest Revision: 20220224

20250114

PMC8805084

10.3389/fimmu.2021.796640

35116030